Imugene Ltd
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more
Imugene Ltd - Asset Resilience Ratio
Imugene Ltd (IMU) has an Asset Resilience Ratio of 28.74% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1995–2025)
This chart shows how Imugene Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Imugene Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$21.94 Million | 26.24% |
| Short-term Investments | AU$2.08 Million | 2.49% |
| Total Liquid Assets | AU$24.02 Million | 28.74% |
Asset Resilience Insights
- Very High Liquidity: Imugene Ltd maintains exceptional liquid asset reserves at 28.74% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Imugene Ltd Industry Peers by Asset Resilience Ratio
Compare Imugene Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Imugene Ltd (1995–2025)
The table below shows the annual Asset Resilience Ratio data for Imugene Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 2.49% | AU$2.08 Million | AU$83.59 Million | -31.20pp |
| 2024-06-30 | 33.69% | AU$51.01 Million | AU$151.40 Million | +8.55pp |
| 2023-06-30 | 25.14% | AU$49.54 Million | AU$197.06 Million | +5.49pp |
| 2022-06-30 | 19.65% | AU$29.00 Million | AU$147.61 Million | -9.60pp |
| 2021-06-30 | 29.25% | AU$21.00 Million | AU$71.81 Million | -9.10pp |
| 2020-06-30 | 38.34% | AU$25.00 Million | AU$65.20 Million | -17.52pp |
| 2019-06-30 | 55.87% | AU$17.20 Million | AU$30.78 Million | +9.62pp |
| 2018-06-30 | 46.25% | AU$7.82 Million | AU$16.91 Million | +8.27pp |
| 2017-06-30 | 37.97% | AU$4.81 Million | AU$12.68 Million | -- |
| 2016-06-30 | 0.00% | AU$0.00 | AU$9.54 Million | -- |
| 1996-06-30 | 4.18% | AU$387.00K | AU$9.25 Million | +0.33pp |
| 1995-06-30 | 3.86% | AU$460.00K | AU$11.93 Million | -- |